Equillium, a Nasdaq-listed biotech company, has acquired Bioniz Therapeutics in a deal worth up to around $329 million, in a move to considerably expand its pipeline of novel immunomodulatory drug candidates. Bioniz Therapeutics, which is based in Irvine, California, is a clinical-stage biopharma company focused on developing precision cytokine targeted therapies for treating immuno-inflammatory diseases. […]
Roivant Sciences has agreed to merge with Montes Archimedes Acquisition (MAAC), a Nasdaq-listed special purpose acquisition company, in a deal that values the Swiss biopharma company at $7.3 billion. Montes Archimedes Acquisition is sponsored by health care investment firm Patient Square Capital. The deal is expected to enable Roivant Sciences to get a listing on […]
AI drug discovery software company Model Medicines has signed a multi-target collaboration agreement with California-based Sanford Burnham Prebys Medical Discovery Institute for identifying and developing drugs for novel antiviral targets. The collaboration will make use of Model Medicines’ ActivPred AI Drug Discovery Platform, a drug, target, and disease agnostic digital chemistry engine, in conjunction with […]
Roivant Sciences has agreed to acquire Silicon Therapeutics, a Boston-based drug design, research, and development company, for $450 million, in an all-share deal. The Swiss biopharma company will also make additional payments to the US firm based on regulatory and commercial milestones. Silicon Therapeutics is said to have developed a computational physics platform. The platform […]
PostEra, a biotech company specializing in machine learning solutions for preclinical drug discovery, has forged a partnership with Pfizer for speeding up the discovery of small molecule drugs by using a platform technology based on generative chemistry. The company’s machine learning technology can fast track the drug discovery process by designing novel molecular structures that […]
PharmaEngine has signed a collaboration and license deal with UK-based Sentinel Oncology for advancing the new drug development of SOL-578, a checkpoint kinase 1 inhibitor (Chk1 inhibitor). As per the agreement, the Taiwanese pharma company will finance the investigational new drug (IND) enabling studies for SOL-578. Sentinel Oncology is a drug discovery company engaged in […]
US-based PerkinElmer will acquire UK-based cell engineering company Horizon Discovery Group for nearly $383 million in an all-cash deal. The transaction, which is subject to the meeting of customary closing conditions, expected to be completed in Q1 2021. Through the deal, PerkinElmer will expand its portfolio of automated life sciences discovery and applied genomics solutions […]
US biopharma company Ligand Pharmaceuticals has signed a deal worth up to $516 million to acquire Pfenex, a development and licensing biotechnology company engaged in the development of protein therapeutics, which are used in various commercial and development-stage biopharma drug candidates. As per the terms of the deal, Ligand Pharmaceuticals is offering to acquire the […]
Curi Bio, a developer of human iPSC-based platforms for drug discovery, has acquired Dana Solutions, a provider of artificial intelligence and machine learning technologies for in vitro cell-based assays. Financial terms of the deal were not disclosed by the parties. Curi Bio, through the acquisition, will get access to Dana Solutions’ artificial intelligence and machine […]
Canadian biotech company Cyclica has signed a multi-year and multi-project drug discovery partnership with the Genome Institute of Singapore (GIS) in oncology and related diseases. The partners will undertake research efforts, which will span from polypharmacology profiling to novel compound design for diverse drug discovery programs. The collaboration will utilize the deep expertise of Genome […]